Shares of Transenterix Inc (NYSEAMERICAN:TRXC) have earned an average recommendation of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $3.23.

Several equities analysts have issued reports on TRXC shares. Ladenburg Thalmann Financial Services set a $5.00 target price on Transenterix and gave the stock a “buy” rating in a research report on Friday, October 20th. Stifel Nicolaus reiterated a “buy” rating and set a $4.00 target price (up previously from $3.75) on shares of Transenterix in a research report on Monday, October 30th. Finally, BTIG Research reiterated a “hold” rating on shares of Transenterix in a research report on Monday.

Transenterix (NYSEAMERICAN:TRXC) traded up $0.09 during midday trading on Tuesday, reaching $2.03. The company’s stock had a trading volume of 2,711,021 shares, compared to its average volume of 3,233,670. Transenterix has a 52 week low of $0.45 and a 52 week high of $5.00. The firm has a market cap of $441.12, a PE ratio of -3.27 and a beta of 1.98.

In related news, insider Todd Pope sold 600,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $3.68, for a total value of $2,208,000.00. Following the sale, the insider now owns 462,644 shares in the company, valued at approximately $1,702,529.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Joseph P. Slattery sold 529,609 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $2.80, for a total value of $1,482,905.20. Following the completion of the sale, the chief financial officer now owns 440,974 shares in the company, valued at approximately $1,234,727.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,462,609 shares of company stock worth $4,666,595.

A hedge fund recently raised its stake in Transenterix stock. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 79,150 shares of the medical instruments supplier’s stock after buying an additional 37,000 shares during the quarter. Ladenburg Thalmann Financial Services Inc. owned about 0.05% of Transenterix worth $113,000 at the end of the most recent reporting period.

TRADEMARK VIOLATION NOTICE: “Transenterix Inc (TRXC) Given Consensus Rating of “Hold” by Analysts” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/transenterix-inc-trxc-given-consensus-rating-of-hold-by-analysts/1778715.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with MarketBeat.com's FREE daily email newsletter.